SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001069530-21-000009
Filing Date
2021-02-12
Accepted
2021-02-12 17:09:54
Documents
8
Period of Report
2021-02-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sava-20210212x8k.htm 8-K 47384
2 EX-5.1 sava-20210212xex5_1.htm EX-5.1 17875
3 EX-10.1 sava-20210212xex10_1.htm EX-10.1 252753
4 EX-99.1 sava-20210212xex99_1.htm EX-99.1 18334
5 EX-99.2 sava-20210212xex99_2.htm EX-99.2 23442
6 GRAPHIC sava-20210212xex5_1g001.jpg GRAPHIC 2546
7 GRAPHIC sava-20210212xex99_1g001.jpg GRAPHIC 15020
8 GRAPHIC sava-20210212xex99_2g001.jpg GRAPHIC 15020
  Complete submission text file 0001069530-21-000009.txt   406444
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29959 | Film No.: 21629376
SIC: 2834 Pharmaceutical Preparations